# IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

> **NCT05411757** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shandong Public Health Clinical Center** · enrollment: 12 (estimated)

## Conditions studied

- Advanced Primary Liver Cancer

## Interventions

- **COMBINATION_PRODUCT:** IBR900 combined with Lenvatinib
- **COMBINATION_PRODUCT:** IBR900 combined with Bevacizumab

## Key facts

- **NCT ID:** NCT05411757
- **Lead sponsor:** Shandong Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411757, "IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05411757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*